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ranscription factors, often characterized as undrug-
gable, are nonetheless emerging as potentially attrac-
tive therapeutic targets due to their fundamental role
in human disease.1–6 One class of transcription fac-
tors, transcriptional activators, plays a key regulatory
role by binding to DNA and assembling the transcriptional
machinery at a particular gene, thus stimulating gene expres-
sion. Miscued transcription caused by malfunctioning activa-
tors has been implicated in the onset of many cancers and
this has spurred widespread interest in the development of
small and large molecules that directly target misregulated
genes.2–5 The development of small molecule transcriptional
activation domain (TAD) mimics is an advantageous strategy
to modulate transcription because, similar to natural TADs,
these molecules can function as activators when tethered to a
DNA-binding domain (DBD) and as inhibitors when not
localized to DNA (Figure 1a).6 TAD mimics are thus
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ABSTRACT:
Previously it was demonstrated that amphipathic
isoxazolidines are able to functionally replace the
transcriptional activation domains of endogenous
transcriptional activators. In addition, in vitro binding
studies suggested that a key binding partner of these
molecules is the CREB Binding Protein (CBP), more
specifically the KIX domain within this protein. Here we
show that CBP plays an essential role in the ability of
isoxazolidine transcriptional activation domains to
activate transcription in cells. Consistent with this model,
isoxazolidines are able to function as competitive
inhibitors of the activators MLL and Jun, both of which
utilize a binding interaction with KIX to up-regulate
transcription. Further, modification of the N2 side chain
produced three analogs with enhanced potency against
Jun-mediated transcription, although increased
cytotoxicity was also observed. Collectively these small
KIX-binding molecules will be useful tools for dissecting
the role of the KIX domain in a variety of pathological
processes. # 2010 Wiley Periodicals, Inc. Biopolymers 95:
17–23, 2011.
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promising candidates for modulating gene transcription, for
use as mechanistic probes, and as transcription-targeted
therapeutics.6
Like their natural counterparts, small molecule TADs
must interact with coactivators in the transcriptional
machinery in order to function. This presents a formidable
challenge since the number of putative coactivator targets of
activators is large, with few validated as physiologically rele-
vant.7 One target of importance is the CREB binding protein
(CBP), a large (265 kDa) multidomain coactivator and
histone acetyl transferase.8,9 CBP integrates transcriptional
signals from [100 transcription factors and is an essential
protein for cell growth and development. In contrast to most
coactivators, the individual domains of CBP have proven
amenable to structural characterization and, concomitantly,
have been attractive targets for the development of small and
large molecule transcriptional regulators.10–16 A domain that
has attracted much attention in this regard is the KIX do-
main, an 87-residue module whose solution structure has
been elucidated.17 Despite its relatively small size, the KIX
domain contains at least two activator binding sites,
the CREB/Myb site and the MLL/Jun/Tat/Tax site (Figure
1b).18–23 Screening against the KIX domain has led to the
discovery of both peptides and peptidomimetic TADs that
function well in cells11,24; derivatives of these peptides have
been useful tools for defining characteristics of activator
binding sites.25 Not just useful for creating activators, a small
molecule screen against the KIX domain has also yielded
naphthol AS-E phosphate and related derivatives that com-
petitively inhibit the KIX-CREB binding interaction.14,16
Complementary to genetic strategies, compounds that in-
hibit KIX-binding activators will be useful tools in dissecting
the role of the KIX domain in physiological processes such as
cell differentiation and hematopoiesis.26–29 Furthermore,
both MLL and Jun have been implicated in several cancers,
including leukemias and solid tumors30–35; thus compounds
that block these proteins from forming key interactions with
CBP may prove useful in the development of transcription-
targeted therapeutics.1–9,36
We identified several isoxazolidine-based TADs through a
top-down discovery strategy that reconstitute the function of
a natural activator when localized to a promoter (e.g. 1a,
Figure 1c).37–39 Subsequent in vitro binding studies revealed
that one target of these small molecules is the KIX domain of
CBP, more specifically the MLL/Jun/Tat/Tax site within that
domain (Figure 1b).12 What was not clear from these studies
was if this interaction is essential for function in a cellular
context. Here we provide evidence that the isoxazo-
lidine CBP interaction is required for cellular activity. Con-
sistent with this model, in the absence of DNA binding,
isoxazolidine 1 is able to competitively inhibit transcription
mediated by the KIX-dependent activators MLL and c-Jun.
Based on natural peptide ligands for KIX, alteration of the
aromatic side chain of 1 led to the identification of two mol-
ecules with enhanced potency, although increased cytotoxic-
ity was also observed.
FIGURE 1 (a) Transcriptional activators, minimally comprised of
a DNA-binding domain (DBD; blue oval) and a transcriptional acti-
vation domain (TAD; red rectangle), upregulate transcription by
stimulating chromatin remodeling and facilitating the assembly of
the RNA polymerase II holoenzyme at a promoter.66 The TAD is
primarily responsible for the direct binding interactions with the
transcriptional machinery (gold) in order to accomplish this. Poten-
tial binding partners of TADs within the transcriptional machinery
include enzymes that modify chromatin, the proteasome, and/or
coactivators. Small or large molecule mimics of TADs can serve as
competitive inhibitors of activators, thus down-regulating transcrip-
tion. b) The two activator-binding sites within the KIX domain of
CBP/p300. Highlighted in green in the space-filling diagram of the
KIX domain are the residues that experience the greatest chemical
shift perturbation upon interacting with the TAD of MLL as meas-
ured by 1H-15N-HSQC experiments;19 the TADs of Tat, Tax, and
Jun occupy a similar binding site.21–23 In red are the amino acids
that change when interacting with Myb.36 Pymol figures were gener-
ated from 1kdx. (c) Isoxazolidine-based mimics of transcriptional
activation domains. DBD5 OxDex conjugated to an ethylene glycol
linker (AEEA).37–39
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RESULTS AND DISCUSSION
Cellular Activity of 1 Depends Upon CBP
Previously we demonstrated that amphipathic isoxazolidine
1 activates transcription and interacts with the KIX domain
of CBP, while 2, bearing an alkene in place of the hydroxyl
functional group at C3, does not activate nor does it interact
with KIX.12,37–39 To assess if CBP is required for 1-mediated
transcriptional activity, the impact of lowering CBP concen-
trations via shRNA knockdown was examined in the pres-
ence of 1 conjugated to the glucocorticoid receptor (GR)
ligand OxDex (1a).40 In these experiments, cells were trans-
fected with a luciferase reporter bearing five Gal4 binding
sites and a plasmid encoding a fusion protein of the Gal4
DBD and the minimal ligand binding domain of GR in the
presence of 1a. In this two-hybrid assay, molecules tagged
with the GR ligand OxDex will interact with the fusion pro-
tein and thus be localized to DNA.11 The knockdown of CBP
with shRNA resulted in an 86 6 8% decrease (from 70-fold
to 12-fold) in 1a-driven luciferase expression, while a
scrambled shRNA had no effect (see Supporting Information
Figure S1). Additionally, the expression of exogenous CBP
partially rescued the activity of 1a (from 12- to 50-fold, see
Supporting Information Figure S1. In contrast, increased
CBP concentration had no impact on the ability of isoxazoli-
dine 2a to activate transcription, suggesting there is a direct
link between CBP concentration and 1a-driven activation.
Additionally, a change in CBP concentration had no effect on
expression of a luciferase gene driven by a CMV promoter
that does not contain Gal4 binding sites (see Supporting In-
formation Figure S2). Taken together, these data reveal that
the activity of 1a is directly impacted by CBP concentration
in the cell.
Another common strategy for altering cellular CBP avail-
ability is to use the viral protein E1A to sequester it.41–44 As
shown in Figure 2, there is an 80 6 3% decrease (from 70-
fold to 15-fold) in isoxazolidine 1a-mediated activation
when E1A is present. In sum, modulation of transcriptional
activity by affecting the availability of CBP supports the
model that 1a functions as a transcriptional activator recruit-
ment of CBP in a cellular context.
Inhibition of MLL and Jun
Although a number of natural TADs interact with the KIX
domain,19,21,44,45 the isoxazolidine TADs were the first exam-
ples of small molecules that interact with the site utilized by
the amphipathic TADs of MLL, Jun, Tat, and Tax.12 The
overlapping binding footprint of 1b with that of MLL and
Jun should enable the small molecule to function as a com-
petitive inhibitor of these activators. Towards this end, a se-
ries of activator competition studies were performed using
proteins composed of the MLL and Jun TADs and the DBD
of Gal4. Although 1b is considerably smaller than the mini-
mal TADs for MLL and Jun, it was able to inhibit the activa-
tion of both MLL and Jun in a dose-dependent manner
(Figure 3a). The EC50 for inhibition of Jun by 1b is 19 lM
and for inhibition of MLL it is 36 lM. In addition, ESX, an
activator that is not known to bind the KIX domain was not
inhibited in a similar series of experiments. This is consistent
with previous results performed in two ESX-driven cell
lines where 1 exhibits inhibition only at high concentrations
( 50 lM).46
The previous reporter gene experiments demonstrated
that 1b inhibits the minimal TAD of Jun. It was unclear,
however, if the isoxazolidine would function in a similar
manner with the full-length Jun protein in an endogenous
promoter context. To assess if inhibition of native Jun could
be accomplished with isoxazolidine 1b, we chose to examine
expression of the cyclin D1 protein, a key component of the
cell cycle machinery.48–52 Cyclin D1 expression is regulated
FIGURE 2 Isoxazolidine-driven gene expression requires CBP.
HeLa cells were transfected with a plasmid encoding the DBD of
Gal4 fused to the ligand-binding domain of the glucocorticoid re-
ceptor (500 ng/mL), a firefly luciferase reporter plasmid containing
five Gal4 binding sites (500 ng/mL), and a Renilla transfection con-
trol (10 ng/mL). Additional plasmids were transfected as indicated
for CBP (100 ng/mL), CBP shRNA (100 ng/mL), and E1A (100 ng/
mL) experiments. Four hours post-transfection, 10 lM 1a was
added as a solution in DMSO such that the final concentration of
DMSO was 1% (v/v). Luciferase output was measured 24h after
addition of compound; fold activation is a ratio of firefly and
Renilla luminescence divided by the ratio of firefly and Renilla signal
observed with DBD alone. Each value represents at least three indi-




by the AP-1 transcription factor that is a Jun homo- or a
Jun-Fos heterodimer.35,53–55 As illustrated in Figure 3b, treat-
ment of Jun-expressing MCF-7 breast cancer cells with 40
lM 1b (a concentration two-fold higher than the EC50) led
to a significant decrease in cyclin D1 expression. In the same
time course, expression of Jun was minimally impacted while
the control, GAPDH, was unchanged. Thus, isoxazolidine 1b
exerts an inhibitory effect on expression of a Jun-regulated
gene not only in an artificial reporter system, but also in a
native context. The demonstration of isoxazolidine 1b-medi-
ated inhibition of a Jun-regulated gene is a key step in devel-
oping a new chemical tool for probing the Jun pathway.
Inhibition of MLL and Jun With N2 Analogs
Although the results of Figure 3a illustrate that isoxazolidine
1b serves as a transcriptional inhibitor, concentrations
[ 20 lM are required. For these molecules to serve as probes
of KIX function, an increase in potency is highly desirable.
Like a peptide, the isoxazolidine is a modular scaffold, ame-
nable to functionalization at the N2, C3, C4, and C5 posi-
tions. Thus, to design new molecules with increased potency,
we looked to natural KIX-binding peptides for functional
groups. The sequences of several natural TADs that bind the
MLL/Jun/Tat/Tax site of the KIX domain (Figure 4a) possess
diverse amphipathic sequences. Whereas Tax and Jun only
possess aliphatic hydrophobic side chains, Tat and MLL
TADs contain aromatic side chains from tryptophan and
phenylalanine, respectively. These sequence differences may
contribute to the range of dissociation constants observed
for these activators (MLL 5 2.5 lM,19 Tat 5 11 lM,20 Jun 5
30 lM54), though this has not been determined. In the case
of the isoxazolidine scaffold, an isoxazolidine bearing a
biphenyl substituent at the N2 position (3) does not bind the
KIX domain or activate transcription;12,56 thus we used
biphenyl as an upper limit on steric modification. Early in
our studies, we observed that a smaller substituent, p-
hydroxyphenyl (4), did not negatively impact KIX binding by
1H-15N-HSQC binding experiments (Supporting Informa-
tion Figure S4). Thus, to assess the functional impact of aro-
matic and aliphatic substituents at the N2 position of 1, a
small series of isoxazolidines was prepared bearing function-
ality similar to that of natural activators (4, 7-9) and small
steric (5) and electronic (6) modifications.
While 1b and 4 exhibit no measurable toxicity at concen-
trations  50 lM, the remaining analogs inhibited cell
growth at concentrations above 10 lM, limiting the range of
concentrations that could be examined (see Supporting In-
formation Figure S3). As expected, biphenyl 3 did not affect
Jun-driven transcription; in addition, compounds 4, 8, and 9
exhibited little activity. However, as shown in Figures 4c and
S5, isoxazolidines 5, 6, and 7 inhibited Jun transcriptional ac-
tivity in a dose-dependent manner. Indeed, these three com-
pounds are more effective than 1 (1.3- to 2-fold greater inhi-
bition at 10 lM). The levels of inhibition achieved by these
molecules is higher for Jun than for MLL, perhaps a reflec-
tion of the[10-fold difference in the dissociation constants
of these two activators (Supporting Information Figure S5).
Despite the improved activity of isoxazolidines 5-7 relative
to 1, none of the three exhibit submicromolar EC50s; this
highlights one of the challenges of designing small molecule
transcriptional modulators, which possess a much smaller
surface area relative to their peptidic counterparts.57–60 While
the isoxazolidine shares an overlapping binding surface with
FIGURE 3 Inhibition of KIX-targeting TADs by 1b. (a) Isoxazoli-
dine 1b decreased Jun and MLL minimal TAD-driven activation in
a dose-dependent manner while not affecting ESX, an activator that
is not known to bind the KIX domain.47 Cells were transfected with
Firefly (500 ng/mL) and Renilla luciferase (10 ng/mL) plasmids in
addition to plasmids encoding the DBD of Gal4 fused to the mini-
mal activation domains of either MLL (250 ng/mL), Jun (100 ng/
mL), or ESX (500 ng/mL, 0.1 mL of total transfection solution).
Four hours post-transfection cells were treated with increasing con-
centration of 1b (0 ? 50 lM) as a solution in DMSO such that the
final DMSO concentration was 1% (v/v). Percent inhibition is the
ratio of fold activation of Jun at each concentration of compound
and the fold activation of Jun in a DMSO-treated control. Each bar
represents at least three independent experiments with the indicated
error (SDOM). (b) MCF-7 cells were treated with 40 lM 1b (as a
solution in DMSO such that the final concentration of DMSO was
1% v/v) for 24 h, at which time the cells were lysed and the lysates
separated by SDS-PAGE. Western blots were performed using com-
mercial antibodies against GAPDH, Jun, and cyclin D1.
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that of Jun and MLL, the peptidic ligands for KIX interact
with a significantly larger area of the domain and make more
intermolecular contacts that contribute both to binding
affinity and specificity.12,19,21 To more substantially increase
potency, it may be necessary to utilize a small molecule
framework that can incorporate additional functional groups
for interaction with the KIX domain, such as dimeric isoxa-
zolidines, for example.12 In addition, we note that recent
advances with cell-permeable, constrained peptides have
shown promising results in inhibiting activators that interact
with other domains of CBP.15
In summary, here we have demonstrated that the isoxazo-
lidine transcriptional activation domain mimic 1 requires
CBP for cellular function and, consistent with this mecha-
nism, 1 can competitively inhibit the ability of the native
KIX-dependent activators Jun and MLL to function. Investi-
gation of analogs of 1 led to the identification of three addi-
tional Jun and MLL-inhibitors with improved potency. These
inhibitors will be useful tools for further dissecting the role
of the KIX domain in a variety of physiological and patho-
logical processes either alone or in combination with mole-
cules that target other sites within CBP and/or its HAT activ-
ity.8,14,61–63 The answers to these questions will further define
the role of CBP in small molecule-mediated gene expression
and provide a platform for development of new classes of
small molecule transcriptional modulators.
MATERIALS AND METHODS
Plasmids
The murine-CBP expression plasmid pRC/RSV-m CBP-HA64 and
the 12S E1A expression plasmid, pBabe 12S E1A65 were purchased
from Addgene. Plasmid Gal4-MLL(2829-2883) was constructed by
PCR amplification of the MLL minimal activation domain (residues
2829–2883)44 from a full length MLL plasmid containing an N-ter-
minal flag tag, (F-MLL, a gift from Dr. Jay Hess) using PCR primers
(50-GACTGGATCCCT GAAATCAGATTCAGACAATAAC-30 and 50-
CAAGGCGGCCGCA AGACCCAATCCTTCACCAAG-30. The PCR
product was digested with BamH1 and Not1 and ligated into the
plasmid pCMV-Gal4 using standard molecular biology techniques.
The plasmid pTKGG encoding the DNA binding domain of Gal4
fused to the minimal ligand binding domain of the glucocorticoid
receptor was the generous gift of Dr. Tom Kodadek. The plasmid
encoding the Jun TAD fused to the Gal4 DBD and the luciferase re-
porter plasmids, pG5luc and pRLSV40, were purchased from Prom-
ega. The CBP shRNA construct was prepared as previously
described.40
Transcriptional Inhibition Assay
HeLa cells (10,000 per well) were transfected with a Firefly luciferase
reporter (500 ng/mL), and Renilla (10 ng/mL) control plasmid in
addition to a plasmid encoding for either the MLL (250 ng/mL) or
Jun (100 ng/mL) activation domain fused to the DNA-binding do-
main of Gal4 in 0.1 mL Optimem. The Optimem was removed and
0.1 mL of DMEM supplemented with 10% FBS and compound was
FIGURE 4 (a) Sequences of KIX-binding TADs. (b) Analogs of 1b tested for MLL and Jun
inhibition; see Supporting Information for complete details of synthesis and characterization. (c) Inhi-
bition of Jun with isoxazolidine analogs. Inhibition assays were carried out as described in Figure 3a.
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added four hours post-transfection and the luminescence was
assessed after 24 h as described above.
Western Blot
HeLa cells (10,000 per well) were lysed using passive lysis buffer
(Promega) with Complete1, EDTA-free protease inhibitors (Roche)
for 10 min at room temperature on an orbital shaker. Lysates were
centrifuged at 14,000 rpm for 20 min and the supernatant was mixed
with 43 loading dye (Invitrogen) and BME (final concentration of
1%). The samples were then heated at 958C for 10 min, separated by
SDS-PAGE, transferred to a PVDF membrane and probed using
standard conditions. Jun (sc-1694, 1:1000), cyclin D1 (sc-718,
1:1000), CBP (sc-7300, 1:500), and GAPDH (sc-47724, 1:2000) anti-
bodies were all purchased from Santa Cruz Biotechnology.
The authors thank Dr. Ryan Casey for the gift of compound 5 and
Mr. Chris Taylor for a sample of isoxazolidine 3. We appreciate Jeff
Kampf ’s assistance with obtaining the solid state structure of 4.
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